We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -17.00 | -0.94% | 1,795.50 | 1,795.50 | 1,796.00 | 1,802.00 | 1,792.00 | 1,792.50 | 472,653 | 10:45:33 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.99 | 73.86B |
From May 2019 to May 2024
By Sabela Ojea
GlaxoSmithKline PLC said Monday that interim analysis of the HIV Prevention Trials Network 083 study has proved the efficacy and safety of investigational, long-acting, injectable cabotegravir inhibitor for HIV prevention.
The British pharmaceutical giant said that the study of cabotegravir was 69% more effective in preventing HIV acquisition when administered every two months in men who have sex with men and transgender women who have sex with men "when compared to the current standard of care, daily oral emtricitabine/tenofovir" drugs.
The London-listed company added that the study had around 4,600 participants across America, Asia and Africa.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 18, 2020 02:44 ET (06:44 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
